Internal Medicine, Infectious Disease · New Orleans, LA
NPI
1356534168
Since 2007
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1514 Jefferson Hwy
New Orleans, LA, 70121
Phone (504) 842-4000
Groups this clinician bills Medicare through
Medicare paid, 2024
$32K
339 services
Medicare patients, 2024
161
Average age 68
Drug cost, 2024
$2.2M
1,926 prescriptions
Company payments, 2025
$113
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Obinna Nnedu was code 99233 (hospital e&m - subsequent), 151 times for 77 patients. In total Obinna Nnedu billed 339 services in 14 codes, and Medicare paid $32K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-07-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 151 | 77 | $90.55 | $14K |
| 99223 Hospital E&M - Initial | Facility | 82 | 78 | $129.87 | $11K |
| 99214 Office E&M - Established | Facility | 43 | 35 | $69.47 | $2,987 |
| 99215 Office E&M - Established | Facility | 20 | 13 | $89.83 | $1,797 |
By year: 2022 $41K for 447 services; 2023 $40K for 409 services; 2024 $32K for 339 services.
Medicare prescription drug claims, 2024
In 2024, the drug Obinna Nnedu prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 112 prescriptions and refills. In total Obinna Nnedu wrote 1,926 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 112 | 112 | 13 | $442K |
| Tivicay Dolutegravir Sodium | 91 | 91 | 11 | $252K |
| Juluca Dolutegravir/Rilpivirine | 87 | 87 | Under 11 | $297K |
| Descovy Emtricitabine/Tenofov Alafenam | 74 | 74 | Under 11 | $166K |
| Daptomycin Generic | 66 | 66 | 16 | $12K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 60 | 60 | Under 11 | $213K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 58 | 58 | Under 11 | $231K |
| Atorvastatin Calcium Generic | 48 | 94 | Under 11 | $258 |
| Ceftriaxone Ceftriaxone Sodium | 46 | 46 | 11 | $1,116 |
| Doxycycline Hyclate Generic | 42 | 50 | 17 | $784 |
| Amlodipine Besylate Generic | 39 | 87 | Under 11 | $138 |
| Cephalexin Generic | 38 | 46 | Under 11 | $685 |
| Alprazolam Generic | 29 | 32 | Under 11 | $46.45 |
| Atovaquone-Proguanil Hcl Atovaquone/Proguanil Hcl | 28 | 31 | 27 | $2,060 |
| Dovato Dolutegravir Sodium/Lamivudine | 27 | 27 | Under 11 | $77K |
Brand drugs: - claims; generic drugs: 1,222 claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Obinna Nnedu $113 ($113 in general payments such as food, travel and fees) from 1 company. The largest payer was Gilead Sciences, Inc. with $113.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 2 | $113 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.